75
Views
5
CrossRef citations to date
0
Altmetric
Rapid Communication

Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders

, , , , &
Pages 121-127 | Published online: 28 Apr 2014

References

  • GibiinoSSerrettiAParoxetine for the treatment of depression: a critical updateExpert Opin Pharmacother201213342143122263916
  • GillesMDeuschleMKellnerSParoxetine serum concentrations in depressed patients and response to treatmentPharmacopsychiatry200538311812115902581
  • Yasui-FurukoriNNakagamiTKanedaAInverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disordersHum Psychopharmacol201126860260822102561
  • KayeCMHaddockRELangleyPFA review of the metabolism and pharmacokinetics of paroxetine in manActa Psychiatr Scand Suppl198935060752530793
  • SindrupSHBrøsenKGramLFPharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphismClin Pharmacol Ther19925132882951531951
  • JornilJJensenKGLarsenFLinnetKIdentification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulatorDrug Metab Dispos201038337638520007670
  • ZhouSFPolymorphism of human cytochrome P450 2D6 and its clinical significance: Part IClin Pharmacokinet2009481168972319817501
  • TehLKBertilssonLPharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importanceDrug Metab Pharmacokinet2012271556722185816
  • CYP2D6 allele nomenclature [webpage on the Internet]The Human Cytochrome P450 (CYP) Allele Nomenclature Database [updated Jun 21, 2006]. Available from: http://www.imm.ki.se/cypalleles/cyp2d6.htmAccessed December 14, 2013
  • SuzukiYFukuiNTsuneyamaNEffect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patientsHum Psychopharmacol2012271434622745940
  • SakuyamaKSasakiTUjiieSFunctional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47–51, 53–55, and 57)Drug Metab Dispos200836122460246718784265
  • YoonYRChaIJShonJHRelationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjectsClin Pharmacol Ther200067556757610824636
  • SawamuraKSuzukiYSomeyaTEffects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetineEur J Clin Pharmacol200460855355715349705
  • UedaMHirokaneGMoritaSThe impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patientsProg Neuropsychopharmacol Biol Psychiatry200630348649116423440
  • SindrupSHBrøsenKGramLFThe relationship between paroxetine and the sparteine oxidation polymorphismClin Pharmacol Ther19925132782871531950
  • FindlingRLNucciGPiergiesAAMultiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorderNeuropsychopharmacology20063161274128516319918
  • FengYPollockBGFerrellREKimakMAReynoldsCFBiesRRParoxetine: population pharmacokinetic analysis in late-life depression using sparse concentration samplingBr J Clin Pharmacol200661555856916669849
  • Yasui-FurukoriNTsuchimineSNakagamiTAssociation between plasma paroxetine concentration and changes in plasma brain-derived neurotrophic factor levels in patients with major depressive disorderHum Psychopharmacol201126319420021638327
  • SteenVMAndreassenOADalyAKDetection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technologyPharmacogenetics1995542152238528268
  • RamamoorthyYTyndaleRFSellersEMCytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substratesPharmacogenetics200111647748711505218
  • BertelsenKMVenkatakrishnanKVon MoltkeLLObachRSGreenblattDJApparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidineDrug Metab Dispos200331328929312584155
  • SchulzPTurner-TamiyasuKSmithGGiacominiKMBlaschkeTFAmitriptyline disposition in young and elderly normal menClin Pharmacol Ther19833333603666825390
  • TaskerTCKayeCMZussmanBDLinkCGParoxetine plasma levels: lack of correlation with efficacy or adverse eventsActa Psychiatr Scand Suppl19893501521552530776
  • NormannCHörnMHummelBGrunzeHWaldenJParoxetine in major depression: correlating plasma concentrations and clinical responsePharmacopsychiatry200437312312615138896